201 related articles for article (PubMed ID: 25308563)
1. Current chemotherapeutic approaches for recurrent or refractory germ cell tumors.
O'Carrigan B; Grimison P
Urol Oncol; 2015 Aug; 33(8):343-54. PubMed ID: 25308563
[TBL] [Abstract][Full Text] [Related]
2. Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapy.
Sammler C; Beyer J; Bokemeyer C; Hartmann JT; Rick O
Eur J Cancer; 2008 Jan; 44(2):237-43. PubMed ID: 18055194
[TBL] [Abstract][Full Text] [Related]
3. Salvage high-dose chemotherapy for germ cell tumors.
Feldman DR; Powles T
Urol Oncol; 2015 Aug; 33(8):355-62. PubMed ID: 25837842
[TBL] [Abstract][Full Text] [Related]
4. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY
Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide in testicular cancer: the Indiana University experience.
Loehrer PJ; Williams SD; Einhorn LH
Semin Oncol; 1989 Feb; 16(1 Suppl 3):96-101. PubMed ID: 2539649
[TBL] [Abstract][Full Text] [Related]
6. Third-line chemotherapy and novel agents for metastatic germ cell tumors.
Veenstra CM; Vaughn DJ
Hematol Oncol Clin North Am; 2011 Jun; 25(3):577-91, ix. PubMed ID: 21570610
[TBL] [Abstract][Full Text] [Related]
7. High-dose chemotherapy for relapsed testicular germ cell tumours.
Chovanec M; Adra N; Abu Zaid M; Abonour R; Einhorn L
Nat Rev Urol; 2023 Apr; 20(4):217-225. PubMed ID: 36477219
[TBL] [Abstract][Full Text] [Related]
8. High-dose chemotherapy followed by hematological support: experience in the treatment of germ cell tumors.
Pico JL; Fadel E; Ibrahim A; Bourhis JH; Droz JP
Bull Cancer; 1995; 82 Suppl 1():56s-60s. PubMed ID: 7542945
[TBL] [Abstract][Full Text] [Related]
9. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer.
Rick O; Bokemeyer C; Weinknecht S; Schirren J; Pottek T; Hartmann JT; Braun T; Rachud B; Weissbach L; Hartmann M; Siegert W; Beyer J
J Clin Oncol; 2004 Sep; 22(18):3713-9. PubMed ID: 15365067
[TBL] [Abstract][Full Text] [Related]
10. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group.
Lorch A; Kollmannsberger C; Hartmann JT; Metzner B; Schmidt-Wolf IG; Berdel WE; Weissinger F; Schleicher J; Egerer G; Haas A; Schirren R; Beyer J; Bokemeyer C; Rick O;
J Clin Oncol; 2007 Jul; 25(19):2778-84. PubMed ID: 17602082
[TBL] [Abstract][Full Text] [Related]
11. Treatment of relapsed/refractory germ cell tumours: an equipoise between conventional and high dose therapy.
Rashid S; Lim L; Powles T
Curr Treat Options Oncol; 2012 Jun; 13(2):201-11. PubMed ID: 22623055
[TBL] [Abstract][Full Text] [Related]
12. High-dose chemotherapy for male germ cell tumor.
Hara I; Miyake H; Yamada Y; Takenaka A; Fujisawa M
Int J Urol; 2006 Aug; 13(8):1037-44. PubMed ID: 16903926
[TBL] [Abstract][Full Text] [Related]
13. The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors.
Oing C; Lorch A
Oncol Res Treat; 2018; 41(6):365-369. PubMed ID: 29843143
[TBL] [Abstract][Full Text] [Related]
14. Platinum-refractory germ cell tumors: an update on current treatment options and developments.
Oing C; Alsdorf WH; von Amsberg G; Oechsle K; Bokemeyer C
World J Urol; 2017 Aug; 35(8):1167-1175. PubMed ID: 27449639
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapeutic treatment of germ cell tumors: standard of care and recent developments.
Oing C; Seidel C; von Amsberg G; Oechsle K; Bokemeyer C
Expert Opin Pharmacother; 2016; 17(4):545-60. PubMed ID: 26630452
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of salvage high-dose chemotherapy in patients with germ cell tumor with poor prognostic features.
De Giorgi U; Rosti G; Salvioni R; Papiani G; Ballardini M; Pizzocaro G; Marangolo M
Urol Oncol; 2011; 29(3):284-90. PubMed ID: 19556152
[TBL] [Abstract][Full Text] [Related]
17. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database.
Lorch A; Bascoul-Mollevi C; Kramar A; Einhorn L; Necchi A; Massard C; De Giorgi U; Fléchon A; Margolin K; Lotz JP; Germà-Lluch JR; Powles T; Kollmannsberger C; Beyer J
J Clin Oncol; 2011 Jun; 29(16):2178-84. PubMed ID: 21444870
[TBL] [Abstract][Full Text] [Related]
18. Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study.
Wessalowski R; Schneider DT; Mils O; Friemann V; Kyrillopoulou O; Schaper J; Matuschek C; Rothe K; Leuschner I; Willers R; Schönberger S; Göbel U; Calaminus G;
Lancet Oncol; 2013 Aug; 14(9):843-52. PubMed ID: 23823158
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy in patients with metastatic or relapsed germ-cell tumours.
Rick O; Siegert W; Beyer J
Cancer Treat Rev; 2001 Oct; 27(5):283-8. PubMed ID: 11871864
[TBL] [Abstract][Full Text] [Related]
20. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.
Einhorn LH; Williams SD; Chamness A; Brames MJ; Perkins SM; Abonour R
N Engl J Med; 2007 Jul; 357(4):340-8. PubMed ID: 17652649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
